Literature DB >> 19320236

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Ching-Sheng Hsu1, Chen-Hua Liu, Chun-Jen Liu, Chi-Ling Chen, Ming-Yang Lai, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao.   

Abstract

BACKGROUND: Early viral load decline following pegylated interferon-alpha2a and ribavirin therapy is an important predictor of the treatment responses in chronic hepatitis C (CHC) patients, thus, it is essential to evaluate the influence of host and viral factors on early viral load decline.
METHODS: Clinical and serial virological data were collected from 145 consecutive Asian CHC patients with pegylated interferon-alpha2a plus ribavirin therapy. A dose of pegylated interferon-alpha2a was administered at week 1 and then weekly with daily oral ribavirin for 24 or 48 weeks. Genotyping and quantification of hepatitis C virus (HCV) RNA were done using molecular methods.
RESULTS: A total of 81 patients were infected with HCV genotype 1,61 with genotype 2 and 3 with both genotypes 1 and 2. At the end of follow-up, 110 patients attained sustained virological response (SVR). In multivariate analyses, body mass index (BMI) and genotype were related to viral load decline at day 2, baseline viral load and high-density lipoprotein (HDL) cholesterol levels were correlated with viral load decline between days 2 and 28. Genotype, baseline viral load, alanine aminotransferase (ALT) levels and BMI independently predicted rapid virological response, whereas only genotype 2, lower baseline viral load and more substantial viral load decline at day 28 predicted a higher SVR.
CONCLUSIONS: HCV genotype, baseline viral load, pretreatment BMI, HDL and ALT levels have a significant effect on early viral load decline of Asian CHC patients with interferon-based therapy. Only HCV genotype, baseline viral load and viral load decline at day 28 can independently predict SVR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19320236

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  10 in total

1.  Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.

Authors:  Venessa Pattullo; E Jenny Heathcote; David K H Wong
Journal:  Hepatol Int       Date:  2010-08-08       Impact factor: 6.047

2.  Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.

Authors:  K Patel; R Jhaveri; J George; G Qiang; C Kenedi; K Brown; C Cates; A Zekry; H L Tillmann; L Elliott; R Kilaru; J Albrecht; A Conrad; J G McHutchison
Journal:  J Viral Hepat       Date:  2011-05       Impact factor: 3.728

3.  Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.

Authors:  Ching-Sheng Hsu; Shih-Jer Hsu; Hung-Chia Chen; Tai-Chung Tseng; Chen-Hua Liu; Wei-Fang Niu; Jenher Jeng; Chun-Jen Liu; Ming-Yang Lai; Pei-Jer Chen; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

4.  Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients.

Authors:  Ching-Sheng Hsu; Shih-Jer Hsu; Hung-Chia Chen; Chen-Hua Liu; Jenher Jeng; Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2012-07-08       Impact factor: 6.047

5.  Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy.

Authors:  Seyed Vahid Tabatabaei; Seyed Moayed Alavian; Maryam Keshvari; Bita Behnava; Seyyed Mohammad Miri; Pegah Karimi Elizee; Farhad Zamani; Sedigheh Amini Kafiabad; Ahmad Gharehbaghian; Bashir Hajibeigy; Kamran Bagheri Lankarani
Journal:  Hepat Mon       Date:  2012-06-30       Impact factor: 0.660

6.  The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection.

Authors:  Ashraf Mohamadkhani; Kourosh Sayemiri; Reza Ghanbari; Elham Elahi; Hossein Poustchi; Ghodratollah Montazeri
Journal:  Virol J       Date:  2010-09-14       Impact factor: 4.099

7.  Hepatitis C virus load in parenchyma cells correlates with hepatic injury in infected patients.

Authors:  Zhen Xu; Ji-Zong Lin; Guo-Li Lin; Fang-Fang Wei; Jing Liu; Zhi-Xin Zhao; Ying Zhang; Wei-Ming Ke; Xiao-Hong Zhang
Journal:  Exp Ther Med       Date:  2016-11-18       Impact factor: 2.447

8.  Real response to therapy in chronic hepatitis C virus patients: a study from iran.

Authors:  Najmeh Namazee; Shahnaz Sali; Sorour Asadi; Mostafa Shafiei; Bita Behnava; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2012-09-15       Impact factor: 0.660

9.  Evaluated outcomes in patients with Chronic Hepatitis C.

Authors:  Sara Ashtari; Mohsen Vahedi; Mohammad Amin Pourhoseingholi; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013

10.  Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.

Authors:  Ching-Sheng Hsu; Shih-Jer Hsu; Wei-Liang Liu; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.